Faktori rizika i komorbiditeti koji predisponiraju fibrilaciju atrija

  • Marijana C Jandrić-Kočić Dom zdravlja Krupa na Uni, služba porodične medicine

Sažetak


Uvod: Fibrilacija atrija (eng.Fibrillatio atriorum, FA) predstavlja najčešću aritmiju u kličkoj praksi kojom je pogođeno 1-2% svjetske populacije. Karakteriše je visokofrekventna ekscitacija atrija, posljedična asinhron a atrijalna  kontrakcija  i nepravilna ekscitacijaventrikula. Faktori rizika i komorbiditeti  predisponiraju  FA promjenom ekstracelularnog  matiksa, promjenom funkcije fibroblasta i masnih stanica,  jonskih kanala,  miocita,  autonomnog nervnog sistema, endotelnim  i vaskularnim  promjenama.   Cilj: Istraživanje je imalo za cilj utvrditi faktore  rizika i komorbiditete  koji su statistički značajno povezani sa pojavom FA.                          Metode: Istraživanje  je studija presjeka obavljeno u Domu zdravlja Krupa na Uni u periodu od   01. 11. 2017. do 01.01.2019.  Uzorak je činilo 145 slučajno odabranih pacijenata,  96 (66.2%) žena i 49 (33.8%) muškaraca., prosječne starosti  63 ± 9.8 godina. Podaci su prikupljeni putem anamneze, fizikalnog pregleda, elektrokardiograma, laboratorijske dijagnostike, ultrazvučnog pregleda i dostupne medicinske dokumentacije.  Obrada podataka vršena je standardnim statističkim metodama.                                       Rezultati: FA je učestalija kod žena, starijih od 60 godina i osoba koje            konzumiraju alkohol (p  < 0.05). Komorbiditeti povezani sa FA su: hipertrofija lijeve komore, mitralna regurgitacija, hipertenzija, dijabetes,  hronična opstruktivna bolest pluća i gojaznost (p < 0.05).                                                                                          Zaključak: Rana detekcija,  pravovremen i adekvatan  menadžment komorbiditeta i faktora rizika FA  sprečava  ili usporava  napredovanja FA, podiže kvalitet života oboljelih, smanjenjuje  troškove zadravstvene zaštite i radnog apsentizma.

Biografija autora

Marijana C Jandrić-Kočić, Dom zdravlja Krupa na Uni, služba porodične medicine
specijalizacija porodične medicine

Reference

Velagić V. Inducibilost paroksizmalne fibrilacije atrija nakon krioablacije plućnih vena, disertacija. Sveučilište u Zagrebu, Medicinski fakultet; 2017. dostupno na: http://medlib.mef.hr/3079/1/Velagi%C4%87-DIS-2017.pdf.

Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk Factor Management in Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2018; 7(2):118–127. dostupno na:10.15420/aer.2018.18.2

Mashat AA, Subki MA, Bakhaider MA, Baabdullah WM, Walid JB, Alobudi AH, Fekeeh MM, Algethmi AJ, Alhejily WA. Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia. 2019:12:71-77. dostupno na: https://doi.org/10.2147/IJGM.S188524.

Lovrić Benčić M. Fibrilacija atrija – najčešća postojana aritmija. Kardiologija danas. 2016; 25 (2):167-176. dostupno na: https://hrcak.srce.hr/170015.

Ambrosi CM, Yamada KA, Nerbonne JM, Efimov IR. Gender differences in electrophysiological gene expression in failing and non-failing human hearts. PLoS One. 2013; 8(1):e54635. dostupno na:10.1371/journal.pone.0054635.

Voskoboinik A, Prabhum S, Ling L, Kalman JM, Kistler PM. Alcohol and Atrial Fibrillation. Journal of the American College of Cardiology. 2016; 68 (23): 2567-2576. dostupno na: 10.1016/j.jacc.2016.08.074.

A Suzuki, Shinya et al. Association between smoking habits and the first-time appearance of atrial fibrillation in Japanese patients: Evidence from the Shinken Database. Journal of Cardiology, 2015; 66 (1): 73 – 79. dostupno na: https://doi.org/10.1016/j.jjcc.2014.09.010.

Lin YK, Chen YA, Lee TI, Chen YC, Chen SA, Chen YJ. Aging Modulates the Substrate and Triggers Remodelling in Atrial Fibrillation, Circulation Journal. 2018; 82 (5): 1237-1244. dostupno na: https://doi.org/10.1253/circj.CJ-17-0242.

Seko Y, Kato T, Haruna T, Izumi T, Miyamoto S, Nakane E & Inoko M. Association between atrial fibrillation, atrial enlargement, and left ventricular geometric remodelling. Scientific Reports. 2018; 8 (6366): 2045-2322. dostupno na: https://doi.org/10.1038/s41598-018-24875-1.

Ferreira JP, Santos M. Heart failure and atrial fibrillation: from basic science to clinical practice. Int J Mol Sci. 2015; 16(2):3133–3147. Published 2015 Jan 30. dostupno na:10.3390/ijms16023133

Ionin V, Zaslavskaya E.L, Belyaeva O.D, Soboleva A.V, Bazhenova, E.A, Jatzuk, D.I, Nifontov S.E, Polyakova E.A, Baranova E.I, Shlyachto E.V. Atrial fibrillation and heart failure. Journal of Hypertension. 2016; 34. dostupno na: https://10.1097/01.hjh.0000491389.87478.d7.

Grigioni F, Avierinos JF, Ling LH, Scott CG, Bailey KR, Tajik AJ, Frye RL, Enriquez-Sarano M. Atrial fibrillation complicating the course of degenerative mitral regurgitation: Determinants and long-term outcome. Journal of the American College of Cardiology.2002,40 (1): 84-92. dostupno na: https://doi.org/10.1016/S0735-1097(02)01922-8.

Aronow WS. Hypertension associated with atrial fibrillation. Ann Transl Med. 2017; 5(23):457. doi:10.21037/atm.2017.10.33. dostupno na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733333/.

Mikhail S. Dzeshka, Farhan Shahid, Alena Shantsila, Gregory Y.H. Lip, Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes, American Journal of Hypertension, 2018; 30 (8): 733–755. dostupno na: https://doi.org/10.1093/ajh/hpx013.

European Heart Journal.2018; 39 (33): 3021-3104. dostupno na: https://doi.org/10.1093/eurheartj/ehy339

Aknes TA, Schneider MP, Kjeldsen SE, Wachtell K, Schmjeder RE. Atrial Fibrillation And Renin Angiotensin System Blockade In hypertension. European Cardiology. 2009:5(2):63-68. dostupno na: http://dx.doi.org/10.15420/ecr.2009.5.2.63.

Aknes TA, Schneider MP, Kjeldsen SE, Wachtell K, Schmjeder RE. Atrial Fibrillation And Renin Angiotensin System Blockade In hypertension. European Cardiology. 2009:5(2):63-68. dostupno na: http://dx.doi.org/10.15420/ecr.2009.5.2.63.

Krittayaphong R, Rangsin R, Thinkhamrop B, et al. Prevalence and associating factors of atrial fibrillation in patients with hypertension: a nation-wide study. BMC Cardiovasc Disord. 2016; 16:57. dostupno na: 10.1186/s12872-016-0232-4.

Tadić M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. Data Archives of cardiovascular diseases, 2015: 108 (4): 269-76. dostupno na: https://doi.org/10.1016/j.acvd.2015.01.009.

Bohne LJ, Johnson D, Rose RA, Wilton SB and Gillis AM. The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights. Front. Physiol. 2019; 10:135. dostupno na: 10.3389/fphys.2019.00135.

Hayami, N., Sekiguchi, A., Iwasaki, Y. K., Murakawa, Y., and Yamashita, T. No additional effect of DPP-4 inhibitor on preventing atrial fibrosis in streptozotocin-induced diabetic rat as compared with sulfonylurea. Int. Heart J. 2016. 57, 336–340. dostupno na: 10.1536/ihj.15-266.

Hsueh, W., Abel, E. D., Breslow, J. L., Maeda, N., Davis, R. C., Fisher, E. A., et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res. 2007; 100, 1415–1427. dostupno na: 10.1161/01.RES.0000266449.37396.1f.

Shah V, Desai T, Agrawal A. The Association between Chronic Obstructive Pulmonary Disease (COPD) and Atrial Fibrillation: A Review. Chron Obstruct Pulmon Dis.2016; 1:2. dostupno na: 10.21767/2572-5548.100002.

Grymonprez M, Vakaet V, Kavousi M, Stricker B.H, Ikram M.A., Heeringa J, Oscar H. Franco OH, Brusselle G.G, Lahousse L. Chronic obstructive pulmonary disease and the development of atrial fibrillation. International Journal of Cardiology. 2019; 276: 118-124. dostupno na: https://doi.org/10.1016/j.ijcard.2018.09.056.

Chen X, Lin M, Wang W. The progression in atrial fibrillation patients with COPD: a systematic review and meta-analysis. Oncotarget. 2017; 8(60):102420–102427. dostupno na:10.18632/oncotarget.22092.

Chrishan Joseph Nalliah, Prashanthan Sanders, Hans Kottkamp, Jonathan M. Kalman. The role of obesity in atrial fibrillation, European Heart Journal.2017; 37 (21):1565–1572. dostupno na: https://doi.org/10.1093/eurheartj/ehv486.

Lavie C, Pandey A, Lau DH,. Alpert MA, Sanders P. Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise. Journal of the American College of Cardiology. 2017: 70 (16): 2022-2035. dostupno na: https://doi.org/10.1016/j.jacc.2017.09.002.

Kim EJ, Lyass A, Wang N, et al. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J. 2013; 167(1):123–126. dostupno na:10.1016/j.ahj.2013.10.012.

Kolettis TM, Tsatsoulis A. Subclinical Hypothyroidism: An Overlooked Cause of Atrial Fibrillation? J Atr Fibrillation. 2012; 5(4):710. dostupno na:10.4022/jafib.710.

Selmer C , Olesen J.B, Hansen M.L, Lindhardsen J , Schjerning Olsen AM, Clausager J, Madsen J.G, Faber J, Hansen P.R, Pedersen O.D, Torp-Pedersen C, Gislason G.H. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012; 345:e7895 dostupno na: 10.1136/bmj.e7895.

Objavljeno
2020/10/25
Rubrika
Originalni naučni članak